IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling by Sheng, Xia et al.
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC
signaling
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L., ... Saatcioglu, F. (2019). IRE1α-XBP1s
pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications, 10, [323].
https://doi.org/10.1038/s41467-018-08152-3
Published in:
Nature Communications
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2019 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
ARTICLE
IRE1α-XBP1s pathway promotes prostate cancer
by activating c-MYC signaling
Xia Sheng1,2, Hatice Zeynep Nenseth1, Su Qu1, Omer F. Kuzu1, Turid Frahnow 3,4, Lukas Simon 3,
Stephanie Greene5, Qingping Zeng5, Ladan Fazli6, Paul S. Rennie6, Ian G. Mills7, Håvard Danielsen8,9,10,11,
Fabian Theis 3, John B. Patterson5, Yang Jin1,8 & Fahri Saatcioglu1,8
Activation of endoplasmic reticulum (ER) stress/the unfolded protein response (UPR) has
been linked to cancer, but the molecular mechanisms are poorly understood and there is
a paucity of reagents to translate this for cancer therapy. Here, we report that an IRE1α
RNase-speciﬁc inhibitor, MKC8866, strongly inhibits prostate cancer (PCa) tumor growth as
monotherapy in multiple preclinical models in mice and shows synergistic antitumor effects
with current PCa drugs. Interestingly, global transcriptomic analysis reveal that IRE1α-XBP1s
pathway activity is required for c-MYC signaling, one of the most highly activated oncogenic
pathways in PCa. XBP1s is necessary for optimal c-MYC mRNA and protein expression,
establishing, for the ﬁrst time, a direct link between UPR and oncogene activation. In addition,
an XBP1-speciﬁc gene expression signature is strongly associated with PCa prognosis. Our
data establish IRE1α-XBP1s signaling as a central pathway in PCa and indicate that its
targeting may offer novel treatment strategies.
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During cancer development, there is a need for signiﬁcantlyincreased protein synthesis to support heightened pro-liferation and migration. In addition, there is limited
oxygen and nutrient supply to the growing tumor. These events,
among other pathways, and similar to in normal cells, result in
endoplasmic reticulum (ER) stress and activate the unfolded
protein response (UPR) in an attempt to resolve these stresses to
enable survival1,2. If the insult is not resolved, however, prolonged
ER stress and UPR activation initiates mechanisms of cell death.
Previous studies have implicated UPR activation in different
aspects of carcinogenesis and a variety of cancer types3–5. A number
of small molecule drugs were recently identiﬁed to interfere with
various arms of the UPR6. However, potential translation of this
body of knowledge to cancer therapy has been limited to date.
Recent work has shown that UPR has a key role in prostate
cancer (PCa)7, the most commonly diagnosed non-skin cancer
and the second most deadly cancer in Western countries8. PCa is
initially hormone-dependent for growth, which is the basis for
androgen deprivation therapy (ADT); however, most tumors
eventually relapse to castration resistant PCa (CRPC)9. Recently
developed second generation antiandrogens, such as abiraterone
and enzalutamide, as well as speciﬁc chemotherapies, such as
taxanes, have efﬁcacy treating this lethal stage of the disease10.
However, inherent or acquired resistance to these agents remain
major clinical challenges, which makes it imperative to explore
novel therapeutic approaches.
One of the canonical transmembrane sensors of UPR is inositol
requiring-enzyme 1 alpha (IRE1α). Upon activation, IRE1α
cleaves the X-box-binding protein 1 (XBP1) mRNA into a spliced
form that encodes an active transcription factor (XBP1s), which
then activates expression of UPR target genes. We recently found
that androgen signaling, the most central signaling pathway in
PCa, activates the IRE1α arm of UPR11. Consistent with the
importance of this regulation, genetic inhibition of IRE1α or
XBP1 interferes with PCa growth in vitro and in vivo11.
In the present study, we used an optimized IRE1α RNase-
speciﬁc inhibitor, MKC8866, and found that it strongly inhibited
PCa growth in multiple preclinical models in vitro and in vivo.
MKC8866 also had robust synergistic effects in combination with
clinical agents. Critically, RNA sequencing (RNA-seq) analysis of
MKC8866-treated or XBP1 knockdown PCa cells revealed that
IRE1α-XBP1s is essential for c-MYC signaling, a central onco-
genic regulatory pathway in PCa12,13. These results establish
IRE1α-XBP1s signaling as a potential target for alternative
treatment strategies for PCa.
Results
AR and UPR gene expression are correlated in CRPC. We
previously showed that androgen receptor (AR) activated the
IRE1α-XBP1s signaling in LNCaP and VCaP cells that model the
androgen-sensitive state of PCa11. To assess whether this applies
to CRPC, we used two established CRPC models, 22Rv1 and C4-
2B lines, both of which are responsive to, but not dependent on,
androgens. Androgens signiﬁcantly upregulated IRE1α and
XBP1s expression, as well as that of XBP1s target P58IPK in both
cell lines (Supplementary Fig. 1a). Consistently, there was a sig-
niﬁcant positive correlation between AR gene expression sig-
nature and IRE1 arm gene expression in four independent gene
expression datasets from patients with both primary and meta-
static PCa, including CRPC (Supplementary Fig. 1b). These data
suggest that androgens are important for IRE1α-XBP1s arm
activation in all phases of PCa.
Discovery and characterization of an optimized speciﬁc IRE1α
inhibitor−MKC8866. MKC8866 (see Fig. 1a for chemical
structure) was optimized and reﬁned from a family of IRE1α-
speciﬁc endoribonuclease inhibitors obtained from a chemical
library screen14–16. Previous characterization of these compounds,
including structural analyses, conﬁrmed its speciﬁcity on IRE1α
RNase activity15. Similar to its earlier versions, MKC8866 potently
inhibited the RNase activity of human IRE1α in vitro with an IC50
of 0.29 μM (Supplementary Fig. 2a). In MM1 myeloma cells,
MKC8866 strongly inhibited DTT-induced XBP1s expression
with an EC50 of 0.52 μM (Supplementary Fig. 2b). Dose titration
experiments in unstressed RPMI 8226 cells corroborated these
data with an IC50 of 0.14 μM (Supplementary Fig. 2c).
In LNCaP PCa cells, MKC8866 suppressed XBP1s expression
in a dose-dependent manner under conditions of mild ER stress
(30 nM thapsigargin, TG) with an IC50 of 0.38 μM (Fig. 1b). The
expression of two XBP1s target genes, BiP and P58IPK, were
similarly inhibited, whereas phospho-IRE1α or total IRE1α, or
phospho-eIF2α, levels were not affected (Fig. 1b). Similar results
were obtained in three independent PCa cell lines (VCaP, 22Rv1,
and C4-2B) modeling different stages of PCa (Supplementary
Fig. 2d). MKC8866 suppressed the viability of all four cell lines in
a dose-dependent manner under normal conditions, with the
most robust effect in LNCaP cells (Fig. 1c and Supplementary
Fig. 2e). The efﬁcacy of MKC8866 was further increased in C4-2B
cells under TG-induced mild ER stress (Supplementary Fig. 2f).
Ectopically expressed XBP1s rescued the inhibitory effect of
MKC8866 (Fig. 1d). The levels of ectopically expressed ﬂag-
XBP1s was a few-fold higher compared with endogenous XPB1s;
whereas endogenous XBP1s expression was inhibited by
MKC8866, that of ﬂag-XBP1s was not affected (Supplementary
Fig. 2g). Furthermore, MKC8866 potently impaired XBP1s levels
induced either by androgen treatment (Supplementary Fig. 2h),
or glucose deprivation (Supplementary Fig. 2i). In addition,
MKC8866 had moderate oral bioavailability (30%) in mice, with
maximum concentrations in blood observed at 4 h after oral
administration (Fig. 1e); it also suppressed the tunicamycin (Tm)-
induced XBP1 splicing in mouse liver (Fig. 1f), as well as in mouse
kidney (Fig. 1g). These data suggest that MKC8866 effectively
represses IRE1α-mediated XBP1 splicing in PCa cells and has
favorable pharmacokinetic and pharmacodynamic properties.
IRE1α targeting inhibits PCa cell growth in vitro and in vivo.
We next investigated the potential effect of MKC8866 on PCa cell
growth under various culture conditions. MKC8866 signiﬁcantly
reduced colony formation in all four PCa cell lines tested under
either anchorage-dependent or anchorage-independent condi-
tions (Supplementary Fig. 3a). Prostatosphere growth of these cell
lines, an indication of stemness, was also markedly inhibited in
the presence of MKC8866, which was consistent with IRE1α or
XBP1 knockdown experiments (Supplementary Fig. 3b), sug-
gesting that IRE1α may be involved in mechanisms of tumor
initiation in PCa.
Based on these favorable in vitro results, we next evaluated the
efﬁcacy of MKC8866 in vivo. Consistent with the in vitro
ﬁndings, MKC8866 strongly inhibited xenografted tumor growth
in all PCa cell lines tested (Fig. 2a). XBP1s expression was
signiﬁcantly lower in MKC8866-treated tumors compared to
controls, conﬁrming that MKC8866 was active in mice harboring
the tumors and that IRE1α activity was appropriately inhibited
in vivo (Supplementary Fig. 4a). In addition, there was a decrease
in PCNA expression and an increase in cleaved Caspase-3 levels,
indicating that MKC8866 treatment resulted in decreased
proliferation and increased apoptosis, respectively (Supplemen-
tary Fig. 4b). Removal of MKC8866 during the course of the
treatment resulted in rebounding of XBP1s levels and enhanced
tumor growth (Fig. 2b and Supplementary Fig. 4c), indicating the
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importance of sustained MKC8866 application for its growth
inhibitory effects. These results show that pharmacological
targeting of IRE1α exerts potent antitumor effects in preclinical
mouse models of PCa.
MKC8866 synergizes with clinical PCa drugs in vitro and
in vivo. The striking effect of MKC8866 as monotherapy on PCa
tumor growth in vivo suggests that it can potentially synergize with
drugs that are currently in clinical use for PCa. To assess this, LNCaP
cells were treated with sub-optimal doses of MKC8866 along with
antiandrogens, including abiraterone acetate and enzalutamide, two
drugs that are used in the management of CRPC, as well as taxanes,
including docetaxel, cabazitaxel, and paclitaxel. There was additive
inhibition on LNCaP cell viability when MKC8866 was combined
with either abiraterone acetate, enzalutamide, paclitaxel, or docetaxel,
while clear synergy was seen in combination with cabazitaxel (Sup-
plementary Fig. 5a). In CRPC cell lines 22Rv1 and C4-2B, MKC8866
also showed additive effects with abiraterone acetate in vitro, but
failed to re-sensitize these cells to enzalutamide (Supplementary
Fig. 5b and 5c). These results suggested that there may be enhanced
efﬁcacy of currently used PCa drugs when administered in combi-
nation with MKC8866 in vivo.
In search for a potentially suitable dose of MKC8866 for an
in vivo combination experiment, we reduced its concentration
(200 mg kg−1) or frequency of its administration (every two days)
in a pilot experiment. Daily treatment with the lower dose still
strongly inhibited tumor growth, whereas the normal dose every
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was measured after 3 days. e Mice (n= 3) were orally dosed with indicated amounts of MKC8866 and its plasma concentration was proﬁled post
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08152-3 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:323 | https://doi.org/10.1038/s41467-018-08152-3 | www.nature.com/naturecommunications 3
other day was less effective and was thus chosen for further
combinatorial tests in vivo (Fig. 2c).
There was strong synergy in tumor growth inhibition when
MKC8866 was co-administered with enzalutamide (Fig. 2d).
Hematoxylin and eosin (H&E) staining of the tumors revealed
that combinatorial treatment had the lowest cell content con-
comitant with highest necrosis levels among the different treatment
regimens demonstrating increased efﬁcacy, which was accompanied
by loss of nuclear PCNA expression and marked elevation in
caspase-3 staining (Supplementary Fig. 6a–c). Western analysis
conﬁrmed reduced expression of XBP1s in tumors treated with
both drugs compared to those treated with either vehicle or a single
drug, while no signiﬁcant differences were observed on ATF6α
cleavage or eIF2α phosphorylation, indicating that the other
canonical UPR arms were not affected (Supplementary Fig. 6d).
Co-administration of MKC8866 with abiraterone acetate and
cabazitaxel also synergistically inhibited tumor growth (Fig. 2e, f).
None of the treatments signiﬁcantly affected body weight of mice
(Supplementary Fig. 6e), suggesting that there were no noteworthy
toxicities. Taken together, these data demonstrate that in preclinical
models MKC8866 synergizes with some of the central PCa drug
regimens that are currently used in the clinic.
XBP1s is required for activation of the c-MYC transcriptional
program. MKC8866 speciﬁcally inhibits the RNase activity of
IRE1α thus decreasing XBP1s levels, which should thus be
responsible for the phenotypic effects that we observe in PCa
cells. To gain insight into this process and XBP1s-regulated genes,
we performed RNA-seq analysis in LNCaP cells upon either
XBP1 siRNA-mediated knockdown (siXBP1) or MKC8866-
mediated IRE1α inhibition. Differential gene expression analysis
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of the RNA-seq data was highly concordant amongst experi-
mental replicates for both siXBP1-treated and MKC8866-treated
cells (Supplementary Fig. 7a and 7b). Both approaches robustly
depleted XBP1s expression, indicated by a signiﬁcant decrease in
the mRNA levels of the spliced compared to the unspliced XBP1
isoforms (siXBP1: P < 2.2e−16, MKC8866: P < 2.2e−16, negative
binomial generalized linear model) (Fig. 3a). This was further
conﬁrmed by qPCR analysis of XBP1s mRNA expression, as well
as expression of its target genes RAMP4, EDEM1, and P58IPK
(Fig. 3b). Interestingly, scatter-plot analysis showed that the
down-regulated genes upon XBP1 knockdown and MKC8866
treatment showed high concordance, whereas no strong correla-
tion was observed for the upregulated genes (compare lower left
quadrant with other quadrants, Fig. 3c), indicating that XBP1s
primarily functions as a transcriptional activator in PCa cells.
Consistently, there was signiﬁcant overlap (26 genes) between the
top 100 down-regulated genes (ranked by P value) in each
treatment (P < 2.2e−16, binomial test), whereas the overlap (three
genes) was much smaller between the top 100 upregulated genes
(P < 0.05, binomial test). This suggested that the down-regulated
genes by IRE1α inhibition in PCa cells are largely mediated by
XBP1s. We also validated the RNA-seq data by individual qPCR
analysis of top 10 genes where their expression was inhibited
upon both MKC8866 treatment and XBP1 knockdown (Supple-
mentary Fig. 7c).
Hallmark pathway enrichment analysis of the RNA-seq data
showed that MKC8866 treatment and XBP1 knockdown affected
similar pathways (Fig. 3d). As expected, UPR and Protein
Secretion pathways were both strongly correlated with XBP1
gene expression proﬁle (Supplementary Fig. 8a), mirroring the
established central role of IRE1α-XBP1s signaling in these
processes4,17. Interestingly, among the most highly enriched
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pathways by both treatments was signaling by c-MYC (ranked
ﬁrst in siXBP1 and second in MKC8866 by P value) (Fig. 3d), an
oncoprotein which is very frequently deregulated in cancer12 and
has been centrally implicated in PCa13. XBP1-induced gene
expression changes were positively associated with two different
hallmark signatures for MYC TARGETS, V1 and V2 (Fig. 3e).
Furthermore, Kyoto Encyclopedia of Genes and Genome (KEGG)
analysis demonstrated that the ribosome pathway ranks at the top
in both conditions (Supplementary Fig. 8b and 8c), whereas gene
set enrichment analysis (GSEA) revealed XBP1-deregulated genes
were positively enriched in KEGG ribosome and protein export
(Supplementary Fig. 8d). Together, these data indicate that XBP1
not only affects fundamental aspects of ER biology in PCa cells,
consistent with previous ﬁndings in other tissues, but also
impacts oncogenic c-MYC signaling.
XBP1s directly activates c-MYC expression. To explore whether
XBP1s expression may indeed be linked to c-MYC expression in
PCa, we analyzed published gene expression datasets for human
PCa. Strikingly, there was a positive and strong correlation
between XBP1s and c-MYC target gene expression in 9 out of 11
available cohorts (Fig. 4a, b, and Supplementary Fig. 9a). To
assess whether this correlation extends to the protein level, serial
sections of human prostatectomy samples were examined by
immunohistochemistry for XBP1s and c-MYC. As shown in
Fig. 4c, there was clear colocalization of XBP1s and c-MYC
expression in human PCa specimens. Furthermore, XBP1s and
c-MYC expression was signiﬁcantly correlated in a tissue
microarray (TMA) consisting of 260 human PCa specimens11,18
(Fig. 4d). These results suggest that XBP1s expression is func-
tionally linked to c-MYC signaling in human PCa.
One potential mechanism for these observations is that c-MYC
expression is regulated by the IRE1α-XBP1s axis. In support of
this hypothesis, c-MYC protein expression was inhibited by XBP1
knockdown as well as MKC8866 treatment, in both LNCaP and
VCaP cells, whereas levels of its heterodimer partner MAX
and cofactor TRRAP were not signiﬁcantly affected (Fig. 4e).
Consistently, there was a signiﬁcant decrease in c-MYC mRNA
expression, as well as its target gene expression, represented by
SHMT1, PCNA, MTHFD1, CDC25A, ATF4, and PPAT, whereas
MAX and TRRAP mRNA levels were unchanged upon XBP1
knockdown or MKC8866 treatment (Supplementary Fig. 9b). In
contrast, ectopic expression of XBP1s dose-dependently increased
c-MYC protein expression in LNCaP (Fig. 4f) and VCaP cells
(Supplementary Fig. 9c), which led to an increased resistance to
the bromodomain inhibitor JQ1 (Supplementary Fig. 9d). In
keeping with this ﬁnding, c-MYC immunohistochemical staining
intensity was signiﬁcantly weaker in xenograft tumor sections
from MKC8866-treated mice compared with untreated mice
(Supplementary Fig. 9e). Furthermore, XBP1-knockdown or
MKC8866-mediated inhibition of LNCaP cell viability, colony
formation, as well as prostatosphere growth were rescued, at
least in part, upon inducible expression of c-MYC (Fig. 4g, h).
Similar results were obtained upon c-MYC ectopic expression
(Supplementary Fig. 9f and 9g). In addition, ectopic expression of
ﬂag-XBP1s activated a c-MYC promoter-driven luciferase repor-
ter in a dose-dependent manner in LNCaP (Fig. 4i) and 293T cells
(Supplementary Fig. 9h). TG-induced mild stress also activated
the c-MYC reporter activity in 293T cells, while stronger stress
did not, likely due to the translation inhibition by PERK-eIF2α
activation (Supplementary Fig. 9i). Finally, chromatin immuno-
precipitation (ChIP) analysis showed that XBP1s associated with
two response elements in the c-MYC gene 5ʹ ﬂanking region
(Fig. 4j); consistently, the deletion of these elements in the c-MYC
promoter signiﬁcantly impaired the c-MYC reporter activation in
293T cells (Supplementary Fig. 9j), indicating that XBP1s directly
regulates c-MYC transcription. Together, these data suggest that
the IRE1α-XBP1s axis is required for c-MYC expression and
function in PCa cells.
XBP1 gene expression signature is strongly associated with
PCa prognosis. Integrated analysis of gene expression proﬁles
upon XBP1 knockdown and MKC8866 treatment identiﬁed 733
genes which were signiﬁcantly downregulated by XBP1 knock-
down or MKC8866 (Supplementary Data 1). Next, we evaluated
the possibility that the expression of these genes could serve as
potential prognostic biomarkers for PCa. To assess this, a subset
of signiﬁcantly differentially expressed IRE1α-XBP1s genes was
tested as disease-free survival predictors in three independent
cohorts of PCa patients. To avoid cohort-dependent effects, the
data was quantile normalized. Eventually, a ﬁve-gene combina-
tion, deﬁned as the XBP1 signature, was identiﬁed using an
unbiased prediction and feature selection algorithm for high-
dimensional survival regression19. This ﬁve-gene signature,
including ANLN, CSNK1G3, RRM2, SLC35A2, and UBAC2,
demonstrated remarkable predictive power on disease-free sur-
vival in the TCGA (logrank test, P= 8 × 10−5), MSKCC (logrank
test, P= 7.8 × 10−4), and GSE94767 datasets (logrank test, P=
2.6 × 10−4) (Fig. 5a–c). Further analyses showed signiﬁcant cor-
relation between elevated XBP1 signature gene expression and
shorter biochemical recurrence (BCR)-free survival in the TCGA
(logrank test, P= 1.9 × 10−2), GSE70768 (logrank test, P= 5.9 ×
10−3), and GSE70769 datasets (logrank test, P= 5.5 × 10−4)
(Fig. 5d–f). Taken together, these data show that XBP1 pathway
activation correlates with poor survival in PCa patients and a
gene signature derived from XBP1-regulated genes may have
clinical utility.
Discussion
Previous work has shown that UPR signaling can affect various
aspects of tumor cell biology including angiogenesis, invasion,
mitochondrial function, intercellular communication, tumor-
associated inﬂammation, as well as therapy resistance3–5. How-
ever, potential translational applications for targeting UPR have
largely been missing. Here, we have shown that MKC8866, an
IRE1α RNase-speciﬁc inhibitor molecule, displays signiﬁcant
therapeutic activity in various preclinical models of PCa in vivo.
The major output of IRE1α RNase activity is the synthesis of
the transcription factor XBP1s that was previously implicated in
cancer. XBP1s is overexpressed in a variety of cancers7 suggesting
that it acts as a proto-oncogene. XBP1s overexpression in cancer
cells can directly promote tumorigenesis, such as in chronic
lymphocytic leukemia20, and targeting activated IRE1α and sub-
sequent XBP1 splicing had promising results in preclinical models
in multiple myeloma6. Furthermore, XBP1s interacts with
hypoxia-inducible factor 1-alpha (HIF1α) in triple negative breast
cancer and drives tumor progression by inducing a hypoxia sig-
nature gene expression program21. Interestingly, XBP1 can blunt
antitumor activity by interfering with the function of tumor-
associated dendritic cells22. The XBP1s and ATF6α target,
P58IPK, has also been linked to survival of malignant cells facing
ER stress, mediating an adaptive response to chronic UPR
signaling23.
Despite signiﬁcant knowledge in other malignancies, the
potential function of IRE1α-XBP1s signaling in PCa has not been
clear. We recently found that IRE1α activation has a pro-survival
role in PCa11. The data we presented here show that speciﬁc
inhibition of IRE1α with MKC8866 has remarkable efﬁcacy to
inhibit PCa in mouse models, as well as synergizing with both
targeted and chemotherapeutic drugs that are used against PCa in
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gene expression in ﬁve independent PCa datasets. b The bar graph shows the P values of the correlation between XBP1s and c-MYC target gene expression
in nine different human PCa cohorts, using the Pearson correlation test. c Consecutive sections of human PCa prostatectomy samples were immunostained
for XBP1s and c-MYC. Representative images from one patient at two different magniﬁcations are shown. Scale bars, 100 μΜ (upper panel) and 30 μΜ
(lower panel). d Tissue microarrays containing 260 tumor samples stained with either a XBP1s or c-MYC-speciﬁc antiserum were scored. Dots represent
values of individual samples; thick horizontal lines represent the median; box represents the upper and lower quartile; whiskers represent 1.5 times
interquartile range. The P value indicates the signiﬁcance of correlation between XBP1s and c-MYC scores by ANOVA. e LNCaP or VCaP cells were treated
with either siXBP1 or MKC8866, and c-MYC levels were determined. f LNCaP cells were transfected with either empty vector or ﬂag-XBP1s expression
vector. XBP1s and c-MYC levels were then determined after 2 days. g LNCaP c-MYC inducible cells were treated with either siXBP1 or MKC8866 and then
grown with or without doxycycline (Dox). Cell viability was measured after 3 days. h Same procedure was performed as in g, colony formation (CF) was
measured after 2 weeks while prostatospheres (PS) after 1 week. i LNCaP cells were transfected with 1 μg of pGL3-MYC luciferase reporter plasmid plus
either empty vector (pCDNA3) or the pCDNA3-Flag-XBP1s plasmid. Luciferase activity was determined after 48 h. Results are from a representative
experiment in triplicate. * Indicates statistical differences in LUC values compared to vector-transfected cells (P < 0.05) by Student's t-test. j LNCaP cells
were transfected with either empty pCDNA3 vector (Ctrl) or the pCDNA3-Flag-XBP1s plasmid. After 48 h, ChIP assay was performed using Flag antibody.
The data are representative of two experiments in duplicate. Two responsive sites (#1 and #2) as well as one non-responsive site (#3) are presented.
*P < 0.05, Student's t-test, error bars denote the SD
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the clinic (Fig. 2). This is signiﬁcant as patients either do not
respond, or eventually develop resistance to PCa therapies that
are currently available10. To circumvent the development of
resistance and to achieve the best response, clinical studies are
ongoing to establish combinatorial regimens that have better
efﬁcacy than monotherapies9,24. In this context, MKC8866 could
potentially provide a valuable addition to the spectrum of PCa
therapies, especially in tumors that display elevated IRE1α-XBP1s
activity upon ADT or chemotherapy.
A previous study has made a connection between the UPR and
c-MYC in which PERK-eIF2α-ATF4 signaling was found to
mediate the oncogenic effect of c-MYC by activating cytoprotec-
tive autophagy in lymphomas25. In addition, targeting the kinase
activity PERK with a small molecule inhibitor resulted in anti-
tumor and antiangiogenic activity in multiple preclinical models26.
While these two studies position UPR as a downstream effector of
MYC, the current study is the ﬁrst to show direct activation of
MYC expression and its transcriptional output by one of the
canonical UPR arms. Taken together, and given the central role of
c-MYC in various cancer types, these ﬁndings demonstrate that
there may be a positive feedback loop between MYC and UPR in
cancer, offering opportunities for therapeutic targeting.
Here we demonstrated, for the ﬁrst time, that the central onco-
genic c-MYC signaling pathway, previously shown to have important
roles in PCa progression13, is directly activated by IRE1α signaling
through XBP1s. Consistently, depleting XBP1s either by the IRE1α
RNase-speciﬁc inhibitor MKC8866 or siRNA-mediated knockdown
results in reduced c-MYC levels and tumor regression (Fig. 6). In
addition, XBP1s and c-MYC signaling pathway activation are
remarkably correlated in human PCa cohorts (Fig. 4a and Supple-
mentary Fig. 9a). Rescue experiments established that the tumor
suppressive activity of MKC8866 is, at least in part, due to inhibition
of XBP1s-mediated c-MYC expression (Fig. 4g, h, and Supplemen-
tary Fig. 9e and 9f). Despite its important roles in PCa, as well as in
other cancer types12, previous efforts to inhibit c-MYC function have
not been fruitful27. The bromodomain inhibitor JQ1 suppresses c-
MYC signaling, among its many other effects in PCa, yet our ﬁnd-
ings indicate that high XBP1s tumors may be more resistant to JQ1
(Supplementary Fig. 9d), due to the potentially higher c-MYC levels.
Our ﬁndings raise the possibility that c-MYC can be targeted
through the IRE1α-XBP1s pathway not only in PCa, but also in other
cancer types where c-MYC is important. In addition to c-MYC, our
analyses identiﬁed other signaling pathways that are also involved in
mediating the effects of IRE1α-XBP1s axis in PCa. For example,
mTORC1 signaling and fatty acid metabolism-related signaling
pathways were signiﬁcantly affected by MKC8866 treatment or
XBP1 knockdown (Fig. 4d); these two are mechanistically important
and clinically actionable pathways whose inhibition may synergize
with MKC8866. Further work is required to assess this possibility.
During the review process of this manuscript, a study
demonstrated that c-MYC is critical for the IRE1α-XBP1s path-
way in breast cancer cells by directly activating IRE1α expression
and potentiating XBP1s transcriptional activity28. Consistently,
MKC8866 strongly inhibited c-MYC-driven tumor growth in
preclinical models of breast cancer in vivo. Additional work is
required to establish if XBP1 activates c-MYC expression in
breast cancer cells as well, and whether c-MYC regulates IRE1
expression and XBP1 activity in PCa cells. If so, XBP1s–c-MYC
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axis will provide a strong feedback loop that establishes a pro-
survival pathway in cancer cells that could be targeted at multiple
sites for potential therapeutic applications.
PCa is largely indolent: thus, one of the most challenging
aspects in the clinic is to identify PCa cases that have an
aggressive phenotype compared with the slow-growing, non-
dangerous tumors. In this regard, the XBP1s gene signature that
we have identiﬁed has signiﬁcant predictive power for disease-free
or BCR-free survival in various cohorts (Fig. 5). Additional stu-
dies are required to test the utility of this gene signature for
disease stratiﬁcation in the clinic.
In summary, these data demonstrate the pivotal pro-survival
role of IRE1α-XBP1s signaling in PCa cells and identify
MKC8866 as a candidate drug that could be used in future clinical
trials. In addition, our ﬁndings establish a direct link between
UPR signaling and oncogene activation.
Methods
Cell culture. The human PCa cell lines LNCaP and 22Rv1 were purchased from
the American Type Culture Collection (LGC Standards); the VCaP cell line was a
kind gift of Frank Smit (Radboud University Nijmegen Medical Centre, The
Netherlands); the C4-2B cell line was a generous gift of Leland Chung (Cedars-
Sinai Medical Center, CA). Cells were routinely kept in a humidiﬁed 5% CO2 and
95% air incubator at 37 °C in RPMI 1640 containing 10% fetal bovine serum (FBS),
5 mg ml−1 penicillin/streptomycin, and 2 mM L-glutamine (Lonza). The LNCaP c-
MYC inducible cell line was cultured in RPMI with 10% FBS+ puromycin
(2 μg ml−1) and geneticin (50 μg ml−1)29. The hormone responsiveness and
expression of proteins characteristic to each cell line were tested on a regular basis.
For hormone responsiveness experiments, cells were plated in full medium con-
taining 10% FBS and then preincubated in medium containing 5% charcoal-treated
(CT)-FBS for 3 days before the induction with the synthetic androgen R1881
(1 nM) for the indicated time periods. All cell lines were routinely tested and were
negative of mycoplasma contamination.
Reagents. XBP1 siRNA was purchased from Santa Cruz (sc-38627), Allstar
Negative Control siRNA was from Qiagen (SI03650318), the human pCDNA3-
Flag-XBP1s expression plasmid was from GenScript (OHu25513), the pCDNA3-
HA-c-MYC was a gift from Martine Roussel (Addgene plasmid # 74164)30, and the
pGL3-basic and pGL3-MYC luciferase reporter plasmids were kindly provided by
Odd Stokke Gabrielsen31.
MKC8866 was obtained from Fosun Orinove. Abiraterone acetate (200030) and
enzalutamide (201821) were purchased from Medkoo Biosciences. Docetaxel
(S1148) and cabazitaxel (S3022) were from Sellekchem and Paclitaxel (P-9600)
was from LC Laboratories. JQ1 was a kind gift from Stefan Knapp.
Cell viability assay. Cells were plated in 96-well plates, treated and grown for
3 days. Cell viability was determined using the Cell Count Kit-8 (CCK-8) (Sigma)
according to the manufacturer’s instructions.
Colony formation assay. Brieﬂy, cells were trypsinized, seeded on plastic dishes
(attached) or on top of 0.4% low-melting agarose (unattached), and cultured for the
indicated time periods. The cells were then ﬁxed and stained with 0.1% crystal
violet, and the total area covered by the colonies was measured using an imaging
system (Syngene).
Prostatosphere assay. Cells (1000 cells ml−1) were cultured in suspension in
serum-free DMEM-F12 (BioWhittaker) supplemented with B27 (1:50, Invitrogen),
20 ng ml−1 EGF (E9644, Sigma), 20 ng ml−1 FGF2 (F0291, Sigma), and 4 μg ml−1
insulin (I9278, Sigma). For propagation, spheres were collected by gentle cen-
trifugation, dissociated to single cells and then cultured to generate prostatospheres
of the next generation. Spheres were imaged after growth for 10 days, and areas
covered by spheres was measured and quantiﬁed by ImageJ.
Quantitative PCR. Total RNA was isolated using the TRI Reagent (Sigma-Aldrich,
T9424) according to the manufacturer’s instructions and 1 μg of RNA was reverse
transcribed using Superscript II (Invitrogen 18064014). The cDNA was used in
qPCR whose primer sequences are listed in the Supplementary Information
(Supplementary Table 1). A standard curve made from serial dilutions of cDNA
was used to calculate the relative amount of the different cDNAs in each sample.
The values were normalized to the relative amount of the internal standard
GAPDH. The experiments were performed in triplicate and repeated thrice with
consistent results.
Western analysis. Cells were washed once in ice-cold phosphate-buffered saline
(PBS) and lysed in radioimmunoprecipitation assay (RIPA) buffer (0.1% SDS, 1%
NP-40, 0.5% sodium deoxycholate, 50 mM Tris–HCl pH 8.8, 150 mM NaCl) and
cell lysates were boiled at 95 °C for 5 min. Protein samples were then resolved by
SDS–PAGE and transferred to a PVDF membrane (Bio-Rad). The blotted mem-
brane was blocked in 5% nonfat dry milk in Tris-buffered saline (TBS) containing
0.1% Tween (TBS-Tween) for 1 h followed by incubation with primary antibody in
TBS-Tween containing 5% bovine serum albumin (BSA) for 14–16 h at 4 °C. c-
MYC (32072; 1:1000), MAX (199489; 1:1000), and TRRAP (73546; 1:1000) antisera
were from Abcam; XBP1s (12782; 1:1000), IRE1α (3294S; 1:1000), phospho-eIF2α
(9721L; 1:1000), eIF2α (9722S; 1:1000), BiP (3183; 1:1000), and P58IPK (2940;
1:1000) were from Cell Signaling; AR (sc-816; 1:500), XBP1 (sc-7160; 1:500),
ATF6α (sc-166659; 1:500), and GAPDH (sc-47724; 1:2000) were from Santa Cruz;
phospho-IRE1α was from Thermo Scientiﬁc (PA1-16927; 1:500); TMPRSS2
was from Epitomics (2770-1; 1:1000). The membranes were then incubated with
horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG (Sigma-
Aldrich) secondary antibodies in 5% nonfat dry milk dissolved in TBS-Tween for
1 h at room temperature. ECL Western blotting analysis system was utilized for
detection of the immunoreactive bands according to the manufacturer’s
Tumor progression
BiP
AR ARXBP1
XBP1s
XBP1s
XBP1s
XBP1s
c-MYC
c-MYC c-MYC
c-MYC
c-MYC
XBP1
BiP
P
R1881
P
R1881
IRE1α
BiP
BiP
IRE1α
Stressors Stressors
MKC8866/
siXBP1
Tumor regression
Fig. 6 A schematic summary of the present ﬁndings. In PCa cells, the androgen receptor (AR) directly activates IRE1α expression, that can also be induced
by various stressors on the cell. IRE1α then splices XBP1 mRNA and allows for XBP1s generation. XBP1s transcriptionally induces c-MYC expression, a
potent oncoprotein that contributes to tumor progression (left panel). MKC8866 or siXBP1 inhibit XBP1s expression, resulting in signiﬁcantly decreased
c-MYC levels leading to tumor regression (right panel)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08152-3 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:323 | https://doi.org/10.1038/s41467-018-08152-3 | www.nature.com/naturecommunications 9
instructions (Amersham Pharmacia Biotech). Uncropped gels of the representative
Western blot results are shown in Supplementary Fig. 10.
Luciferase reporter assay. LNCaP or 293T cells were cultured in six-well plates,
transfected with 1 μg of pGL3-MYC luciferase reporter plasmid plus either empty
vector (pCDNA3) or the pCDNA3-Flag-XBP1s plasmid of the indicated con-
centration for 24 h before harvest. Luciferase activity was determined using a
luciferase assay system (Promega) and a Wallac Victor2 1420 Multilabel counter
(Perkin Elmer).
Chromatin immunoprecipitation. ChIP experiments were carried out according to
the standard protocol (Upstate Biotechnology) with some modiﬁcations. Brieﬂy,
cells were treated as indicated before cross-linking with 1% formaldehyde at 37 °C.
The cells were then quenched with 125 mM glycine. Chromatin was sheared using
the Bioruptor sonicator (Diagenode). After centrifugation, sheared chromatin was
immunoprecipitated overnight with a Flag antibody (A00187, GenScript), or
mouse IgG. Antibody bound chromatin complexes were then immunoprecipitated
with protein A-agarose beads, and eluted in SDS buffer. Formaldehyde cross-
linking was reversed at 65 °C overnight, followed by DNA puriﬁcation. Immuno-
precipitated DNA, as well as input DNA, was quantiﬁed by qPCR using speciﬁc
primer sets as indicated. Primer sequences are available upon request.
Xenografts. All procedures on mice, including mouse strain, sex, age, number of
animals allowed, and housing, were conducted according to an experimental
protocol approved by the University of Oslo Institutional Animal Care and Use
Committee. Brieﬂy, cells were grown in vitro and for each injection suspended in
50 μl RPMI-1640 medium and mixed with 50 μl matrigel (BD Biosciences). The
mixture was then subcutaneously inoculated into male nude mice (BALB/c Nu/Nu,
5 weeks of age) in both hind ﬂanks.
After palpable tumors appeared, the mice were randomly grouped and daily
received either 300 mg kg−1 MKC8866 or vehicle (1% microcrystalline in 1 g ml−1
sucrose). For the combinatorial experiment of MKC8866 and enzalutamide, mice
were assigned into four groups (n= 6 per group): oral gavage of 300 mg kg−1
MKC8866 every other day, oral gavage of 30 mg kg−1 enzalutamide every other
day, a combination of daily gavage of either MKC8866 or enzalutamide, and daily
gavage of either MKC8866 or 0.5% HP methyl cellulose with 0.1% Tween 20 as a
vehicle control. The four groups (n= 6 per group) for the combination of
MKC8866 and abiraterone acetate were: oral gavage of 300 mg kg−1 MKC8866
every other day, oral gavage of 20 mg kg−1 abiraterone acetate every other day,
a combination of two treatments, and corresponding vehicles. The four groups
(n= 6 per group) for the combination of MKC8866 and cabazitaxel were: oral
gavage of 300 mg kg−1 MKC8866 every other day, intraperitoneal injections of 5
mg kg−1 cabazitaxel twice a week, a combination of two treatments, and
corresponding vehicles. Tumor weight was measured in the end of experiment.
For assessment of potential synergistic effects: assuming the fractional response to
drug A alone is Fa, and similarly that of drug B alone is Fb, synergy is deﬁned when
the combinatorial fractional response Fc > Fa*(1− Fb). For a review see ref. 32.
Histological and immunohistochemical staining. After de-parafﬁnization, the
tumor sections were ﬁrst stained with hematoxylin and then eosin following the
manufacturer’s guidelines (Thermo Fisher Scientiﬁc) for histological evaluation.
Necrotic content was scored and quantiﬁed using ImageJ. For immunohis-
tochemistry, antigen retrieval was done by autoclaving at 120 °C for 10 min in
10 mM citrate buffer (pH 6.4) following de-parafﬁnization. The primary antibodies
PCNA (P8825, Sigma; 1:200), cleaved caspase-3 (#9664, Cell Signaling; 1:200),
c-MYC (32072, Abcam; 1:100), and XBP1s (a kind gift from Eric Chevet; 1:200)33
were used for overnight incubation at 4 °C. The Supersensitive Detection kit
(Biogenex) was used for antigen detection.
Primary prostate tumors were prospectively collected at the Norwegian Radium
hospital, University of Oslo, and consecutive tumor sections were generated for
immunohistochemical analysis of XBP1s and c-MYC colocalization. The study was
approved by the South-East Norway Health Authority Regional Ethics Committee.
Human PCa specimens (n= 260) were obtained from Vancouver Prostate
Centre Tissue Bank. The H&E slides were reviewed, and the desired areas were
used to construct TMAs (Beecher Instruments, MD, USA). All specimens were
from radical prostatectomies. IHC was conducted by Ventana auto-stainer model
Discover XT (Ventana Medical System, Tuscan, Arizona) with enzyme-labeled
biotin streptavidin system and solvent-resistant DAB Map kit. For scoring, values
on a four-point scale were assigned to each immunostain. Descriptively, 1
represents no apparent staining or very weak level of staining, 2 represents a faint
or focal, questionably present stain, 3 represents a stain of convincing intensity in a
minority of cells, and 4 represents a stain of convincing intensity in a majority of
cells. SPSS 10.0 software was used for IHC statistical analysis.
RNA sequencing. For siXBP1 group, LNCaP cells were reverse-transfected with
either Allstar control siRNA or XBP1 siRNA, after 2 days the cells were treated
with 30 nM TG for 3 h; for MKC8866 group, LNCaP cells were treated with either
DMSO or 10 μM MKC8866 for 1 day before being induced with 30 nM TG for 3 h.
After RNA extraction, the sequencing was performed at the Norwegian Sequencing
Center, where the TruSeq stranded RNA sample prep kit was used for library
generation, and 150 bp paired end sequencing was performed using an Illumina
HiSeq 3000 instrument (Illumina, Inc.). All sequence data sets have been submitted
to GEO (GSE103864).
Gene expression quantiﬁcation. Raw sequencing reads were aligned onto the
human reference genome (hg38) using the STAR software (version 2.5.2)34. Read
summarization was performed using the featureCounts function of the Subread
package35 and the gene annotation ﬁle Homo_sapiens.GRCh38.85.gtf downloaded
from the ENSEMBL annotation server.
XBP1 isoform expression quantiﬁcation. Isoform-speciﬁc XBP1 expression was
quantiﬁed using the splice-loci output generated from the STAR alignments. The
relative abundance of the spliced XBP1 isoform was estimated as the number of
spliced reads that mapped from chr22: 28,796,122 to chr22: 28,796,147 (hg38) per
million total spliced reads. Differential expression of isoform levels was evaluated
using a negative binomial generalized linear model as implemented in the glm.nb
function of the MASS R package. To account for differences in library depth, the
total number of reads sequenced was added as an additional covariate into the
model.
Differential expression analysis. Differential expression analysis was conducted
using the R statistical software in conjunction with the DESeq2 package36. In short,
samples were normalized for sequencing depth using the standard DESeq2 func-
tion estimateSizeFactors. The DESeq2 modeling framework is based on the negative
binomial distribution and uses the DESeq2 normalized gene counts as input. Two
independent models were used to test differential expression between the siXBP1
and siCtrl and between the MKC8866 and vehicle groups. Analysis was restricted
to genes with more than ﬁve counts in at least one sample per group.
Overlap analysis. To assess the statistical signiﬁcance of overlap between the top
100 differentially expressed genes in the two treatments, a binomial test was used.
The hypothesized probability of success was estimated as 100 divided by the
number of genes included in the differential expression analysis.
Hallmark pathway enrichment analysis. Hallmark pathway enrichment analysis
was performed to help the interpretation of the set of up-regulated or down-
regulated genes derived from the differential expression analyses. The hallmark
gene set annotation was downloaded from the Molecular Signature Database v6.0
(http://software.broadinstitute.org/gsea/msigdb/index.jsp). This annotation con-
tains 50 gene sets and each gene set was independently tested for enrichment.
To statistically assess the enrichment, we performed a Kolmogorov–Smirnov test
comparing the distribution of log2 fold changes between genes annotated to a
given gene set and all other genes.
Bioinformatics analysis. The concordance of AR activity37 and expression of
IRE1-regulated genes38 in PCa specimens is evaluated using the published data-
sets39–42. The samples were stratiﬁed into two groups based on AR activity levels,
and expressions of prominent IRE1-regulated genes were compared. The statistical
signiﬁcance was determined by t-test.
The transcriptional activity of XBP1s was scored using a gene set including 36
XBP1s speciﬁc targets generated from this study and a previous report38. The
transcriptional activity of c-MYC was predicted using the SCHUHMACHER_
MYC_TARGETS_UP43. The correlation between XBP1s signaling and c-MYC
signaling was evaluated using published PCa gene expression datasets, including
TCGA cohort41, MSKCC cohort40, SU2C cohort39, GSE9476742, GSE5446044,
GSE7076845, GSE691946,47, GSE1656048, GSE3598849, GSE7793050, and
GSE707651.
RNA-seq data were analyzed using GSEA software to identify functionally
related groups of genes (gene sets) with statistically signiﬁcant enrichment52,53. The
XBP1s-regulated genes identiﬁed here were subjected to differential expression
analysis in normal and cancer tissues of prostate from multiple published PCa
datasets39–42. Genes that showed signiﬁcant increase in tumor compared with
benign prostate were used in survival analysis with multiple PCa cohorts. Genes
whose expression associated with poor prognosis were selected for further analysis.
For identiﬁcation of potential XBP1s sites in the c-MYC ﬂanking regions, we
have used the transcription-binding site prediction PROMO program (http://
alggen.lsi.upc.edu/); this was done using the default setting of 15% maximum
matrix dissimilarity rate that is stringent. PROMO uses XBP-1-binding sites
(CTCGAGATG) deﬁned in the TRANSFAC database (version 8.3) (http://
genexplain.com/transfac/) to construct weight matrices for the prediction. Under
the given settings, we identiﬁed three binding regions within the overlapping
parts of the two primer pairs used in the ChIP-qPCR experiment.
Statistical analysis. Data are presented as mean and standard error of mean. All
values were calculated using Microsoft Excel software. The treatment effects in each
experiment were compared by two-sided t-test. Differences between groups were
considered signiﬁcant at P < 0.05.
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Data availability
All relevant data are available within the manuscript and its supplementary
information, or from the authors upon request. Please contact Yang Jin (yang.
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